Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology
Technology in Cancer Research & Treatment · 2026-07 · 25
DOI: 10.1177/15330338261470918 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 21.07.2026. Verfasst von Leyi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Kinesins, Neoplasms, Precision Medicine. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China NSFC, The Cross-Innovation Talent Project of Renmin Hospital of Wuhan University, Hubei Provincial Natural Science Foundation Joint Fund Project.
Abstract (Originalsprache)
Malignant tumors impose a substantial burden on global health, with an urgent unmet need for effective targets to advance precision therapy. As evolutionarily conserved microtubule motor proteins, the kinesin family (KIF) orchestrates fundamental cellular processes (e.g., intracellular transport, cell division) and canonical signaling pathways, including Wnt and Hippo. Notably, recent studies have uncovered their emerging role in regulating tumor metabolism and reshaping the immune microenvironment, where dysregulated KIF expression drives aberrant tumor proliferation. Based on current research, here we synthesize the latest mechanistic insights into KIF-mediated tumor regulation and evaluate their translational potential as next-generation therapeutic targets and biomarkers for precision cancer therapy. KIF-targeted inhibitors have entered clinical trials across multiple cancer types, holding promise as novel anticancer agents to suppress tumor growth and progression, thereby providing valuable therapeutic options for clinical oncology practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Oncology, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Central Hospital, Xiangyang, China.
ORCID-Profile: Leyi Li, Jing Li, Xinyi Zhao, Haohan Zhang, Qibin Song, Yuchao Dan, Lan Li, Jie Wu, Chao Yang, Junju He, Bin Xu
Förderung
- National Natural Science Foundation of China NSFC
- The Cross-Innovation Talent Project of Renmin Hospital of Wuhan University
- Hubei Provincial Natural Science Foundation Joint Fund Project
- Xiangyang Central Hospital’s Institutional Research Project
Zitieren
APA
Li, L., Li, J., Zhao, X., Zhang, H., Song, Q., Dan, Y., Li, L., Wu, J., Yang, C., He, J., & Xu, B. (2026). Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261470918
Vancouver
Li L, Li J, Zhao X, Zhang H, Song Q, Dan Y, et al. Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261470918
BibTeX
@article{Li2026,
author = {Li, Leyi and Li, Jing and Zhao, Xinyi and Zhang, Haohan and Song, Qibin and Dan, Yuchao and Li, Lan and Wu, Jie and Yang, Chao and He, Junju and Xu, Bin},
title = {Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261470918}
}
EUVIMED